The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Zobair M. Younossi, Deirdre Blissett, Robert Blissett, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, Rachel Beckerman – 20 August 2016 – Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is uncertainty around the economic burden of NAFLD. We constructed a steady‐state prevalence model to quantify this burden in the United States and Europe. Five models were constructed to estimate the burden of NAFLD in the United States and four European countries.

Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients

Ryan M. Kwok, Joseph Ahn, Thomas D. Schiano, Helen S. Te, Darryn R. Potosky, Amber Tierney, Rohit Satoskar, Suzanne Robertazzi, Colleen Rodigas, Michelle Lee Sang, Joshua Wiegel, Neal Patel, Janet Gripshover, Mohamed A. Hassan, Andrea Branch, Coleman I. Smith – 20 August 2016 – Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is associated with worse outcomes. The combination of ledipasvir (LDV) and sofosbuvir (SOF) has been approved for HCV treatment after LT, but there are limited data on the effectiveness and safety of LDV/SOF in the “real‐world” setting.

Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments

Deirdre Kelly, Henkjan J. Verkade, Jeremy Rajanayagam, Patrick McKiernan, George Mazariegos, Stefan Hübscher – 20 August 2016 – Liver transplantation (LT) in children now has a 20‐year survival of >80%, but the longterm outcome of these grafts remains uncertain.

Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation

Marco Dioguardi Burgio, Maxime Ronot, Onorina Bruno, Claire Francoz, Valérie Paradis, Laurent Castera, François Durand, Olivier Soubrane, Valérie Vilgrain – 20 August 2016 – The purpose of this article was to compare the results of Response Evaluation Criteria in Solid Tumors (RECIST), modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria for the evaluation of tumor necrosis in patients treated with transarterial chemoembolization before liver transplantation (LT) for hepatocellular carcinoma.

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Zobair M. Younossi, Deirdre Blissett, Robert Blissett, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, Rachel Beckerman – 20 August 2016 – Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is uncertainty around the economic burden of NAFLD. We constructed a steady‐state prevalence model to quantify this burden in the United States and Europe. Five models were constructed to estimate the burden of NAFLD in the United States and four European countries.

Subscribe to